Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 11% Improvement Relative Risk ICU admission 22% Progression 9% c19aspirin.com Lal et al. NCT04323787 Aspirin for COVID-19 Prophylaxis Favors aspirin Favors control
Lal, 21,579 patient aspirin prophylaxis study: 11% lower mortality [p=0.01], 22% lower ICU admission [p<0.0001], and 9% lower progression [p=0.02] https://c19p.org/lal
copied to clipboard
Pre-hospital aspirin use and patient outcomes in COVID-19: Results from the International Viral Infection and Respiratory Illness Universal Study (VIRUS)
Lal et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2022.07.017 (date from earlier preprint), NCT04323787 (history)
5 May 2022    Source   PDF   Share   Tweet
Retrospective 21,579 hospitalized COVID-19 patients mostly in the USA, showing lower risk of mortality and severity with existing aspirin use.
risk of death, 11.0% lower, HR 0.89, p = 0.01, treatment 4,691, control 16,888, adjusted per study, multivariable.
risk of ICU admission, 22.0% lower, HR 0.78, p < 0.001, treatment 4,691, control 16,888, adjusted per study, multivariable.
risk of progression, 9.0% lower, HR 0.91, p = 0.02, treatment 4,691, control 16,888, adjusted per study, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lal et al., 5 May 2022, retrospective, USA, peer-reviewed, 20 authors, study period 15 February, 2020 - 30 September, 2021, trial NCT04323787 (history).
Contact: lal.amos@mayo.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit